{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:23:20Z","timestamp":1790461400881,"version":"4.1.0"},"reference-count":274,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":450,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"European Society for Medical Oncology central funds"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1093\/annonc\/mdy217","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T11:21:55Z","timestamp":1529320915000},"page":"1658-1686","source":"Crossref","is-referenced-by-count":276,"title":["ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"29","author":[{"given":"F.","family":"Honecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Berney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-9700","authenticated-orcid":false,"given":"J.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cohn-Cedermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-P.","family":"Dieckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Foss\u00e5","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Germa-Lluch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Gietema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Haugnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Huddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.S.","family":"Jewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lauritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Oing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ondru\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Papachristofilou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sohaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"St\u00e5hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Tandstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Toner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Horwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1093\/annonc\/mdy217_bb0015","article-title":"Cancer Incidence in Five Continents","author":"Curado","year":"2007","journal-title":"IARC"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10552-014-0486-z","article-title":"International testicular cancer incidence trends: generational transitions in 38 countries 1900\u20131990","volume":"26","author":"Znaor","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1677\/ERC-09-0284","article-title":"Histology-specific risks in testicular cancer in immigrants to Sweden","volume":"17","author":"Hemminki","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0030","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/ijc.28207","article-title":"Congenital malformations and testicular germ cell tumors","volume":"133","author":"Trabert","year":"2013","journal-title":"Int J Cancer"},{"issue":"10029","key":"10.1093\/annonc\/mdy217_bb0035","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(15)00991-5","article-title":"Testicular germ cell tumours","volume":"387","author":"Rajpert-De Meyts","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ijc.23936","article-title":"Risk of contralateral testicular cancer among men with unilaterally undescended testis: a meta analysis","volume":"124","author":"Akre","year":"2009","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jnci\/djp457","article-title":"Familial coaggregation of cryptorchidism, hypospadias, and testicular germ cell cancer: a nationwide cohort study","volume":"102","author":"Schnack","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0050","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1464-410X.2012.11056.x","article-title":"Bilateral testicular germ cell tumours: a systematic review","volume":"110","author":"Zequi","year":"2012","journal-title":"BJU Int"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb0055","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/annonc\/mdp562","article-title":"Second cancers after testicular cancer diagnosed after 1980 in Sweden","volume":"21","author":"Hemminki","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdy217_bb0060","doi-asserted-by":"crossref","first-page":"12891.","DOI":"10.1038\/srep12891","article-title":"Population landscape of familial cancer","volume":"5","author":"Frank","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0065","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2014.12.031","article-title":"Cancer risk in relatives of testicular cancer patients by histology type and age at diagnosis: a joint study from five Nordic countries","volume":"68","author":"Kharazmi","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/andr.304","article-title":"Common variants identified in genome-wide association studies of testicular germ cell tumour: an update, biological insights and clinical application","volume":"3","author":"Litchfield","year":"2015","journal-title":"Andrology"},{"key":"10.1093\/annonc\/mdy217_bb0075","doi-asserted-by":"crossref","first-page":"8690.","DOI":"10.1038\/ncomms9690","article-title":"Identification of four new susceptibility loci for testicular germ cell tumour","volume":"6","author":"Litchfield","year":"2015","journal-title":"Nat Commun"},{"issue":"10","key":"10.1093\/annonc\/mdy217_bb0080","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/bjc.2015.334","article-title":"Polygenic susceptibility to testicular cancer: implications for personalised health care","volume":"113","author":"Litchfield","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdy217_bb0085","doi-asserted-by":"crossref","first-page":"13889.","DOI":"10.1038\/srep13889","article-title":"Quantifying the heritability of testicular germ cell tumour using both population-based and genomic approaches","volume":"5","author":"Litchfield","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0090","first-page":"CD007853","article-title":"Screening for testicular cancer","author":"Ilic","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1464-410x.1999.00048.x","article-title":"The value of central histopathological review of testicular tumours before treatment","volume":"84","author":"Lee","year":"1999","journal-title":"BJU Int"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2559.2005.02207.x","article-title":"The continued value of central histopathological review of testicular tumours","volume":"47","author":"Delaney","year":"2005","journal-title":"Histopathology"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0105","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000478-200205000-00001","article-title":"Malignant Sertoli cell tumors of the testis: a study of 13 examples of a neoplasm frequently misinterpreted as seminoma","volume":"26","author":"Henley","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0110","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PAP.0b013e318159475d","article-title":"The most common, clinically significant misdiagnoses in testicular tumor pathology, and how to avoid them","volume":"15","author":"Ulbright","year":"2008","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clgc.2016.05.005","article-title":"Value of supraregional multidisciplinary review for the contemporary management of testicular tumors","volume":"15","author":"Purshouse","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1093\/annonc\/mdy217_bb0120","series-title":"Dataset for the histological reporting of testicular neoplasms","author":"Berney","year":"2014"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/his.12657","article-title":"Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists","volume":"67","author":"Berney","year":"2015","journal-title":"Histopathology"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014Part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/his.12958","article-title":"Germ cell neoplasia in situ (GCNIS): evolution of the current nomenclature for testicular pre-invasive germ cell malignancy","volume":"69","author":"Berney","year":"2016","journal-title":"Histopathology"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0140","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/PAS.0b013e31827dcc4c","article-title":"Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases","volume":"37","author":"Zhang","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.semdp.2011.10.001","article-title":"Practical issues and pitfalls in staging tumors of the genitourinary tract","volume":"29","author":"Osunkoya","year":"2012","journal-title":"Semin Diagn Pathol"},{"key":"10.1093\/annonc\/mdy217_bb0150","series-title":"AJCC Cancer Staging Manual","author":"AJCC","year":"2017"},{"key":"10.1093\/annonc\/mdy217_bb0155","series-title":". TNM Classification of Malignant Tumours","author":"UICC","year":"2016"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/his.13200","article-title":"UICC drops the ball in the 8th edition TNM staging of urological cancers","volume":"71","author":"Delahunt","year":"2017","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdy217_bb0165","unstructured":"DM Berney, MT Idrees, SK Tickoo et al. Neoplasia of the Testis, Orchidectomy, Histopathology Reporting Guide, 1st edition. International Collaboration on Cancer Reporting, Sydney, Australia. ISBN: 978-1-925687-07-1.2017."},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0170","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/annonc\/mdi175","article-title":"Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review","volume":"16","author":"Hoei-Hansen","year":"2005","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0175","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.0.CO;2-Z","article-title":"Carcinoma in situ of the testis: review of biological and clinical features","volume":"83","author":"Dieckmann","year":"1999","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0180","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.2047-2927.2014.00260.x","article-title":"Contralateral biopsies in patients with testicular germ cell tumours: patterns of care in Germany and recent data regarding prevalence and treatment of testicular intra-epithelial neoplasia","volume":"3","author":"Ruf","year":"2015","journal-title":"Andrology"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2605.1987.tb00161.x","article-title":"Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma","volume":"10","author":"Skakkebaek","year":"1987","journal-title":"Int J Androl"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.eururo.2006.05.051","article-title":"Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy","volume":"51","author":"Dieckmann","year":"2007","journal-title":"Eur Urol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0195","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.eururo.2005.06.008","article-title":"How harmful is contralateral testicular biopsy? An analysis of serial imaging studies and a prospective evaluation of surgical complications","volume":"48","author":"Dieckmann","year":"2005","journal-title":"Eur Urol"},{"issue":"4 Pt 2","key":"10.1093\/annonc\/mdy217_bb0200","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/j.1365-2605.2011.01192.x","article-title":"Screening of subfertile men for testicular carcinoma in situ by an automated image analysis-based cytological test of the ejaculate","volume":"34","author":"Almstrup","year":"2011","journal-title":"Int J Androl"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0205","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1464-410X.1993.tb15921.x","article-title":"Testicular ultrasonography and 18G biopty biopsy for clinically undetected cancer or carcinoma in situ in patients with germ cell tumours","volume":"71","author":"Heikkil\u00e4","year":"1993","journal-title":"Br J Urol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0210","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1365-2605.2008.00923.x","article-title":"Evaluation of testicular biopsies for carcinoma in situ: immunohistochemistry is mandatory","volume":"32","author":"van Casteren","year":"2009","journal-title":"Int J Androl"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0215","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/00313021003767355","article-title":"Intratubular germ cell neoplasia of the testis and its associated cancers: the use of novel biomarkers","volume":"42","author":"Emerson","year":"2010","journal-title":"Pathology"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0220","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdu585","article-title":"Screening for carcinoma in situ in the contralateral testicle in patients with testicular cancer: a population-based study","volume":"26","author":"Kier","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1034\/j.1600-0463.2003.11101101.x","article-title":"Update on the diagnostic safety for detection of testicular intraepithelial neoplasia (TIN)","volume":"111","author":"Kliesch","year":"2003","journal-title":"APMIS"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1442-2042.1996.tb00507.x","article-title":"Histologic diagnostics of early testicular germ-cell tumor","volume":"3","author":"Holstein","year":"1996","journal-title":"Int J Urol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0235","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2013.06.023","article-title":"Sperm concentration, testicular volume and age predict risk of carcinoma in situ in contralateral testis of men with testicular germ cell cancer","volume":"190","author":"Rud","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0240","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/0284186X.2014.953256","article-title":"Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols","volume":"54","author":"Tandstad","year":"2015","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0245","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12094-010-0507-7","article-title":"Bilateral testicular germ cell tumours: a single hospital experience","volume":"12","author":"Morales-Barrera","year":"2010","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy217_bb0250","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/annonc\/mdg373","article-title":"Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy","volume":"14","author":"Foss\u00e5","year":"2003","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1066896907306125","article-title":"Heterogeneous distribution of ITGCNU in an adult testis: consequences for biopsy-based diagnosis","volume":"16","author":"van Casteren","year":"2008","journal-title":"Int J Surg Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0260","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/annonc\/mds579","article-title":"Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer","volume":"24","author":"Beyer","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0265","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00432-003-0437-7","article-title":"The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary","volume":"129","author":"G\u00e9czi","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0270","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1464-410X.2006.06686.x","article-title":"Spermatogenesis in the contralateral testis of patients with testicular germ cell cancer: histological evaluation of testicular biopsies and a comparison with healthy males","volume":"99","author":"Dieckmann","year":"2007","journal-title":"BJU Int"},{"issue":"Special issue 1","key":"10.1093\/annonc\/mdy217_bb0275","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1259\/bjr\/30029741","article-title":"Focal testicular lesions: colour Doppler ultrasound, contrast-enhanced ultrasound and tissue elastography as adjuvants to the diagnosis","volume":"85","author":"Huang","year":"2012","journal-title":"BJR"},{"issue":"12","key":"10.1093\/annonc\/mdy217_bb0280","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrurol.2013.254","article-title":"Contemporary diagnostic work-up of testicular germ cell tumours","volume":"10","author":"Dieckmann","year":"2013","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0285","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1055\/s-0034-1385038","article-title":"Contrast-enhanced ultrasound and real-time elastography for the diagnosis of benign Leydig cell tumors of the testis - a single center report on 13 cases","volume":"35","author":"Lock","year":"2014","journal-title":"Ultraschall in Med"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0290","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ultrasmedbio.2016.03.026","article-title":"Real-time elastography and contrast-enhanced ultrasonography in the evaluation of testicular masses: a comparative prospective study","volume":"42","author":"Schr\u00f6der","year":"2016","journal-title":"Ultrasound Med Biol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0295","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.14132718","article-title":"Differential diagnosis of nonpalpable testicular lesions: qualitative and quantitative contrast-enhanced US of benign and malignant testicular tumors","volume":"273","author":"Isidori","year":"2014","journal-title":"Radiology"},{"issue":"9","key":"10.1093\/annonc\/mdy217_bb0300","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00330-010-2039-5","article-title":"Role of contrast enhanced ultrasound in acute scrotal diseases","volume":"21","author":"Valentino","year":"2011","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0305","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2214\/AJR.09.3256","article-title":"MRI in the characterization and local staging of testicular neoplasms","volume":"194","author":"Tsili","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0310","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1148\/rg.275065172","article-title":"US MR imaging correlation in pathologic conditions of the scrotum","volume":"27","author":"Kim","year":"2007","journal-title":"Radiographics"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0315","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2015.07.044","article-title":"Guidelines on testicular cancer: 2015 update","volume":"68","author":"Albers","year":"2015","journal-title":"Eur Urol"},{"issue":"9","key":"10.1093\/annonc\/mdy217_bb0320","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/annonc\/mdn170","article-title":"[18F]-FDG-PET in clinical stage I\/II non-seminomatous germ cell tumours: results of the German multicentre trial","volume":"19","author":"de Wit","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb0325","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/MNM.0000000000000303","article-title":"The role of 18F-FDG PET\/CT in the management of testicular cancers","volume":"36","author":"Cook","year":"2015","journal-title":"Nucl Med Commun"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0330","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.crad.2008.10.011","article-title":"Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours","volume":"64","author":"Sohaib","year":"2009","journal-title":"Clin Radiol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0335","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1754-9485.2010.02182.x","article-title":"Fusion of high b-value diffusion-weighted and T2-weighted MR images improves identification of lymph nodes in the pelvis","volume":"54","author":"Mir","year":"2010","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0340","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/21681805.2015.1059360","article-title":"The SWENOTECA group: a good example of continuous binational and multidisciplinary collaboration for patients with testicular cancer in Sweden and Norway","volume":"50","author":"Tandstad","year":"2016","journal-title":"Scand J Urol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0345","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clon.2011.09.005","article-title":"UK management practices in stage I seminoma and the Medical Research Council Trial of Imaging and Schedule in Seminoma Testis managed with surveillance","volume":"24","author":"Cafferty","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0350","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2004.07.188","article-title":"2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial","volume":"22","author":"De Santis","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0355","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.juro.2007.10.054","article-title":"The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma","volume":"179","author":"Hinz","year":"2008","journal-title":"J Urol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0360","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000337056","article-title":"Can we rely on PET in the follow-up of advanced seminoma patients?","volume":"88","author":"Siekiera","year":"2012","journal-title":"Urol Int"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0365","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mdr052","article-title":"2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial","volume":"23","author":"Bachner","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0370","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00259-013-2624-3","article-title":"18F-FDG PET\/CT impact on testicular tumours clinical management","volume":"41","author":"Ambrosini","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1093\/annonc\/mdy217_bb0375","doi-asserted-by":"crossref","first-page":"852681","DOI":"10.1155\/2014\/852681","article-title":"Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis","volume":"2014","author":"Treglia","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0380","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.hoc.2011.03.014","article-title":"Imaging studies for germ cell tumors","volume":"25","author":"Sohaib","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0385","first-page":"815","article-title":"FDG PET for detection and therapy control of metastatic germ cell tumor","volume":"39","author":"Cremerius","year":"1998","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb0390","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2000.1389","article-title":"Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse","volume":"83","author":"Hain","year":"2000","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0395","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.1996.14.5.1637","article-title":"Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients","volume":"14","author":"Stephens","year":"1996","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0400","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.eururo.2014.07.001","article-title":"A nationwide cohort study of stage I seminoma patients followed on a surveillance program","volume":"66","author":"Mortensen","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/andr.280","article-title":"Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience","volume":"3","author":"Cohn-Cedermark","year":"2015","journal-title":"Andrology"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0410","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdy217_bb0415","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2002.01.038","article-title":"Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis","volume":"20","author":"Warde","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0420","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cam4.324","article-title":"Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance","volume":"4","author":"Chung","year":"2015","journal-title":"Cancer Med"},{"issue":"12","key":"10.1093\/annonc\/mdy217_bb0425","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/j.1442-2042.2010.02645.x","article-title":"Outcome of different post-orchiectomy management for stage I seminoma: Japanese multi-institutional study including 425 patients","volume":"17","author":"Kamba","year":"2010","journal-title":"Int J Urol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0430","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/annonc\/mdg241","article-title":"Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma","volume":"14","author":"Aparicio","year":"2003","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1093\/annonc\/mdy217_bb0435","doi-asserted-by":"crossref","first-page":"8717","DOI":"10.1200\/JCO.2005.01.9810","article-title":"Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study","volume":"23","author":"Aparicio","year":"2005","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1093\/annonc\/mdy217_bb0440","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1200\/JCO.2011.36.0503","article-title":"Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group Study","volume":"29","author":"Aparicio","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy217_bb0445","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/annonc\/mdu437","article-title":"Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)","volume":"25","author":"Aparicio","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy217_bb0450","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1200\/JCO.1992.10.11.1762","article-title":"Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party","volume":"10","author":"Read","year":"1992","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1093\/annonc\/mdy217_bb0455","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2013.53.5831","article-title":"Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort","volume":"32","author":"Daugaard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0460","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.0.CO;2-A","article-title":"Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis","volume":"83","author":"Heidenreich","year":"1998","journal-title":"Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb0465","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/annonc\/mdv180","article-title":"A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion","volume":"26","author":"Lago-Hernandez","year":"2015","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb0470","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/annonc\/mdw164","article-title":"Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)","volume":"27","author":"Tandstad","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0475","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1034\/j.1600-0463.2003.11101111.x","article-title":"Surveillance in stage I testicular cancer","volume":"111","author":"Daugaard","year":"2003","journal-title":"APMIS"},{"issue":"13","key":"10.1093\/annonc\/mdy217_bb0480","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","article-title":"Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program","volume":"27","author":"Tandstad","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0485","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/annonc\/mdp473","article-title":"Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy","volume":"21","author":"Kollmannsberger","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0490","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.eururo.2010.12.010","article-title":"Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience","volume":"59","author":"Sturgeon","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0495","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eururo.2011.05.038","article-title":"EAU guidelines on testicular cancer: 2011 update","volume":"60","author":"Albers","year":"2011","journal-title":"Eur Urol"},{"issue":"11","key":"10.1093\/annonc\/mdy217_bb0500","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/annonc\/mdu375","article-title":"One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA Group","volume":"25","author":"Tandstad","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0505","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1200\/JCO.2009.26.4655","article-title":"Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19\/EORTC 30982 study (ISRCTN27163214)","volume":"29","author":"Oliver","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0510","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000474497","article-title":"Phase II study: adjuvant single-agent carboplatin therapy for clinical stage I seminoma","volume":"31","author":"Krege","year":"1997","journal-title":"Eur Urol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0515","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.1996.14.4.1106","article-title":"Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report","volume":"14","author":"Cullen","year":"1996","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1093\/annonc\/mdy217_bb0520","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.2007.12.0899","volume":"26","author":"Albers","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0525","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/JCO.2016.69.0958","article-title":"Outcome of men with relapse after adjuvant carboplatin for clinical stage I seminoma","volume":"35","author":"Fischer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdy217_bb0530","doi-asserted-by":"crossref","first-page":"vi125","DOI":"10.1093\/annonc\/mdt304","article-title":"Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Oldenburg","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0535","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.eururo.2008.08.022","article-title":"Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective","volume":"54","author":"Rassweiler","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0540","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0022-5347(01)65313-8","article-title":"The role of retroperitoneal lymphadenectomy in mature teratoma of the testis","volume":"157","author":"Heidenreich","year":"1997","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdy217_bb0545","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4172\/2168-9857.1000124","article-title":"Mature and immature teratoma: a review of pathological characteristics and treatment options","volume":"3","author":"Wetherell","year":"2014","journal-title":"Med Surg Urol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0550","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cncr.24145","article-title":"Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection","volume":"115","author":"Svatek","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0555","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.juro.2015.12.082","article-title":"Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation: an international collaboration","volume":"196","author":"Giannatempo","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0560","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(196911)24:5<870::AID-CNCR2820240503>3.0.CO;2-2","article-title":"Current results from therapy of testicular tumors","volume":"24","author":"Boctor","year":"1969","journal-title":"Cancer"},{"issue":"18","key":"10.1093\/annonc\/mdy217_bb0565","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/jnci\/dji278","article-title":"Second cancers among 40,576 testicular cancer patients: focus on long-term survivors","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0570","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2013.551","article-title":"Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma","volume":"110","author":"Horwich","year":"2014","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1093\/annonc\/mdy217_bb0575","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/cncr.28086","article-title":"Outcomes in stage I testicular seminoma: a population-based study of 9193 patients","volume":"119","author":"Beard","year":"2013","journal-title":"Cancer"},{"issue":"30","key":"10.1093\/annonc\/mdy217_bb0580","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0585","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2003.04.173","article-title":"Cardiovascular disease as a long-term complication of treatment for testicular cancer","volume":"21","author":"Huddart","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0590","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.2005.08.003","article-title":"Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328)","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0595","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<823::AID-IJC22>3.0.CO;2-V","article-title":"Radiotherapy for stages I and IIA\/B testicular seminoma","volume":"83","author":"Bamberg","year":"1999","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0600","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/02841860510029581","article-title":"Adjuvant radiotherapy in stage I seminoma: is there a role for further reduction of treatment volume?","volume":"44","author":"Bruns","year":"2005","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0605","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.1999.17.4.1146","article-title":"Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group","volume":"17","author":"Foss\u00e5","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0610","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/j.ijrobp.2012.01.044","article-title":"Radiotherapy treatment planning for testicular seminoma","volume":"83","author":"Wilder","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0615","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2007.10.007","article-title":"Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma","volume":"70","author":"Zwahlen","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0620","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijrobp.2010.11.021","article-title":"Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma","volume":"82","author":"Simone","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdy217_bb0625","first-page":"1","article-title":"Cost analysis of adjuvant management strategies in early stage (stage I) testicular seminoma","volume":"7","author":"Cox","year":"2015","journal-title":"Res Rep Urol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0630","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4103\/0973-1482.140846","article-title":"Adjuvant radiotherapy in stage 1 seminoma: evaluation of prognostic factors and results of survival","volume":"11","author":"Serdar","year":"2015","journal-title":"J Cancer Res Ther"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0635","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","article-title":"Radiotherapy for stages IIA\/B testicular seminoma: final report of a prospective multicenter clinical trial","volume":"21","author":"Classen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0640","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0167-8140(00)00240-1","article-title":"Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone","volume":"59","author":"Patterson","year":"2001","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0645","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0360-3016(97)00155-7","article-title":"Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study","volume":"39","author":"Schmidberger","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0650","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.urolonc.2011.04.004","article-title":"A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma","volume":"31","author":"Domont","year":"2013","journal-title":"Urol Oncol"},{"issue":"33","key":"10.1093\/annonc\/mdy217_bb0655","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1200\/JCO.2007.15.9103","article-title":"Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study","volume":"26","author":"Garcia-del-Muro","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0660","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/annonc\/mdj039","article-title":"Single agent carboplatin for CS IIA\/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG)","volume":"17","author":"Krege","year":"2006","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0665","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/annonc\/mdt148","article-title":"Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0670","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdu447","article-title":"Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes","volume":"26","author":"Giannatempo","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0675","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.clon.2016.02.008","article-title":"Stage II testicular seminoma: patterns of care and survival by treatment strategy","volume":"28","author":"Glaser","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0680","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.eururo.2013.09.004","article-title":"A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study","volume":"65","author":"Fizazi","year":"2014","journal-title":"Eur Urol"},{"issue":"12","key":"10.1093\/annonc\/mdy217_bb0685","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1054\/bjoc.2000.1498","article-title":"A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma","volume":"83","author":"Horwich","year":"2000","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0690","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.1994.12.1.120","article-title":"Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients","volume":"12","author":"Mencel","year":"1994","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0695","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2010.30.1044","article-title":"Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group","volume":"29","author":"Tandstad","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0700","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.2001.19.6.1629","volume":"19","author":"de Wit","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8\u20139","key":"10.1093\/annonc\/mdy217_bb0705","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/0959-8049(92)90505-V","article-title":"The activity of single-agent carboplatin in advanced seminoma","volume":"28A","author":"Horwich","year":"1992","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0710","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6602020","article-title":"Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials","volume":"91","author":"Bokemeyer","year":"2004","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0715","first-page":"75","article-title":"Phase III study: cisplatin combination therapy vs. carboplatin monotherapy in metastasizing seminoma","volume":"30","author":"Clemm","year":"1991","journal-title":"Urologe A"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0720","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3109\/0284186X.2012.714078","article-title":"Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma","volume":"52","author":"Tookman","year":"2013","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb0725","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2001.19.7.2020","article-title":"Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse","volume":"19","author":"Rabbani","year":"2001","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdy217_bb0730","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2005.07.132","article-title":"Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome","volume":"23","author":"Stephenson","year":"2005","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1093\/annonc\/mdy217_bb0735","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1200\/JCO.2007.12.0808","article-title":"Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0740","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1159\/000020197","article-title":"RPLND or primary chemotherapy in clinical stage IIA\/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment","volume":"37","author":"Weissbach","year":"2000","journal-title":"Eur Urol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0745","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1200\/JCO.2004.07.178","article-title":"Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdy217_bb0750","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJM198712033172303","article-title":"Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer","volume":"317","author":"Williams","year":"1987","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0755","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group","volume":"15","year":"1997","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdy217_bb0760","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM198706043162302","article-title":"Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide","volume":"316","author":"Williams","year":"1987","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0765","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2011.37.0171","article-title":"Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983","volume":"30","author":"de Wit","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0770","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/bjc.1998.587","article-title":"Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer","volume":"78","author":"de Wit","year":"1998","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0775","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2016.09.015","article-title":"Prognostic factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study","volume":"71","author":"Kier","year":"2017","journal-title":"Eur Urol"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb0780","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/cncr.11271","article-title":"Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial","volume":"97","author":"Hinton","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0785","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.eururo.2006.10.035","article-title":"Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial","volume":"51","author":"Droz","year":"2007","journal-title":"Eur Urol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0790","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/annonc\/mdu485","article-title":"High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study","volume":"26","author":"Necchi","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0795","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2005.05.4528","article-title":"Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0800","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2014.06.034","article-title":"A randomised phase 2 trial of intensive induction chemotherapy (CBOP\/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05\/014, ISRCTN 53643604)","volume":"67","author":"Huddart","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0805","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/annonc\/mdq575","volume":"22","author":"Daugaard","year":"2011","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy217_bb0810","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1023\/A:1008333229936","article-title":"Identification of prognostic subgroups among patients with metastatic \u2032IGCCCG poor-prognosis\u2032 germ-cell cancer: an explorative analysis using cart modeling","volume":"11","author":"Kollmannsberger","year":"2000","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0815","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6600999","article-title":"First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial","volume":"89","author":"Bokemeyer","year":"2003","journal-title":"Br J Cancer"},{"issue":"22","key":"10.1093\/annonc\/mdy217_bb0820","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2003.09.035","volume":"21","author":"Schmoll","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0825","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1008388328809","article-title":"First-line high-dose chemotherapy +\/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases","volume":"11","author":"Kollmannsberger","year":"2000","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdy217_bb0830","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S1470-2045(14)70490-5","article-title":"Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1093\/annonc\/mdy217_bb0835","first-page":"5904","article-title":"Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors","volume":"50","author":"Toner","year":"1990","journal-title":"Cancer Res"},{"issue":"19","key":"10.1093\/annonc\/mdy217_bb0840","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.2004.04.008","article-title":"Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors","volume":"22","author":"Fizazi","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy217_bb0845","article-title":"Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT","volume":"34","author":"Fizazi","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0850","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1200\/JCO.1998.16.2.725","article-title":"Primary mediastinal nonseminomatous germ cell tumors: results of modern therapy including cisplatin-based chemotherapy","volume":"16","author":"Fizazi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1093\/annonc\/mdy217_bb0855","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2016.68.7798","article-title":"Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors","volume":"34","author":"Bagrodia","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0860","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jnci\/92.1.54","article-title":"Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors","volume":"92","author":"Hartmann","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0865","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clgc.2014.06.014","article-title":"A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center","volume":"13","author":"Necchi","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0870","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.urolonc.2010.08.005","article-title":"Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience","volume":"30","author":"Rodney","year":"2012","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0875","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1051::AID-CNCR15>3.0.CO;2-R","article-title":"Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors","volume":"88","author":"Ganjoo","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0880","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/ejcts\/ezr252","article-title":"Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers","volume":"42","author":"De Latour","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"issue":"33","key":"10.1093\/annonc\/mdy217_bb0885","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","article-title":"Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy","volume":"28","author":"Lorch","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0890","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbmt.2012.08.002","article-title":"Salvage therapy with high-dose chemotherapy and peripheral blood stem cell transplant in patients with primary mediastinal nonseminomatous germ cell tumors","volume":"19","author":"Suleiman","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0895","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.hoc.2011.03.012","article-title":"Treatment of brain metastases from germ cell tumors","volume":"25","author":"Oechsle","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"10.1093\/annonc\/mdy217_bb0900","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.ejca.2008.05.012","article-title":"Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy","volume":"44","author":"Oechsle","year":"2008","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0905","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1200\/JCO.1997.15.4.1449","article-title":"Treatment of brain metastases in patients with testicular cancer","volume":"15","author":"Bokemeyer","year":"1997","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy217_bb0910","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12094-014-1179-5","article-title":"Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base","volume":"16","author":"Girones","year":"2014","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0915","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2015.62.7000","article-title":"Brain metastases in patients with germ cell tumors: prognostic factors and treatment options\u2014an analysis from the Global Germ Cell Cancer Group","volume":"34","author":"Feldman","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0920","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ijrobp.2007.11.005","article-title":"Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases","volume":"70","author":"Doyle","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1093\/annonc\/mdy217_bb0925","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.28629","article-title":"Brain metastases associated with germ cell tumors may be treated with chemotherapy alone","volume":"120","author":"Hardt","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0930","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/annonc\/mdw648","article-title":"Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study","volume":"28","author":"Oing","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0935","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00432-012-1169-3","article-title":"Bone metastases in germ cell tumor patients","volume":"138","author":"Oechsle","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0940","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bju.12218","article-title":"Bone metastases in germ cell tumours: lessons learnt from a large retrospective study","volume":"112","author":"Jamal-Hanjani","year":"2013","journal-title":"BJU Int"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0945","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00432-014-1876-z","article-title":"First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database","volume":"141","author":"Oing","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4b","key":"10.1093\/annonc\/mdy217_bb0950","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.1111\/j.1464-410X.2012.11537.x","article-title":"Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours","volume":"111","author":"Miller","year":"2013","journal-title":"BJU Int"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb0955","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clon.2007.11.009","article-title":"Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis","volume":"20","author":"Ramani","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb0960","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000350858","article-title":"Orchidectomy after primary chemotherapy for metastatic testicular cancer","volume":"91","author":"Ramsey","year":"2013","journal-title":"Urol Int"},{"key":"10.1093\/annonc\/mdy217_bb0965","first-page":"407.","article-title":"Role of chemotherapy prior to orchiectomy in metastatic testicular cancer-is testis really a sanctuary site?","volume":"8","author":"Reddy","year":"2014","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0970","doi-asserted-by":"crossref","first-page":"33.e1","DOI":"10.1016\/j.urolonc.2012.12.002","article-title":"Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing","volume":"32","author":"Ruf","year":"2014","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb0975","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euf.2016.10.005","article-title":"Age \u226540 years is associated with adverse outcomes in metastatic germ cell cancer despite appropriate intended chemotherapy","volume":"3","author":"Miller","year":"2017","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb0980","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cncr.28374","article-title":"Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older","volume":"120","author":"Thomsen","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb0985","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mds460","article-title":"Testicular cancer in Europe and the USA: survival still rising among older patients","volume":"24","author":"Verhoeven","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb0990","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/annonc\/mdw045","article-title":"Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014","volume":"27","author":"Adra","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb0995","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2015.64.7909","article-title":"Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy","volume":"34","author":"Ko","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1000","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clgc.2016.07.022","article-title":"A suggested prognostic reclassification of intermediate and poor-risk nonseminomatous germ cell tumors","volume":"15","author":"Necchi","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"14","key":"10.1093\/annonc\/mdy217_bb1005","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/cncr.28025","article-title":"Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older","volume":"119","author":"Feldman","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdy217_bb1010","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1464-410X.2011.10252.x","article-title":"The clinical features and management of testicular germ cell tumours in patients aged 60 years and older","volume":"108","author":"Wheater","year":"2011","journal-title":"BJU Int"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.1998.16.2.716","volume":"16","author":"Foss\u00e5","year":"1998","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1093\/annonc\/mdy217_bb1020","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1200\/JCO.2006.08.7395","article-title":"Rational selection of patients for antibacterial prophylaxis after chemotherapy","volume":"25","author":"Cullen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb1025","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/bmt.2017.106","article-title":"Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database","volume":"52","author":"Necchi","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1093\/annonc\/mdy217_bb1030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/jnci\/91.10.839","volume":"91","author":"Collette","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb1035","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1991.9.5.818","article-title":"Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience","volume":"9","author":"Aass","year":"1991","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.1994.12.2.368","article-title":"After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer","volume":"12","author":"Feuer","year":"1994","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdy217_bb1045","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/jnci\/91.10.816","article-title":"Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer","volume":"91","author":"Feuer","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"10.1093\/annonc\/mdy217_bb1050","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1200\/JCO.2010.29.1278","article-title":"Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group","volume":"29","author":"Olofsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb1055","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/annonc\/mdq551","article-title":"Suboptimal survival of male germ-cell tumors in southern Portugal\u2013a population-based retrospective study for cases diagnosed in 1999 and 2000","volume":"22","author":"Passos-Coelho","year":"2011","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb1060","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.ejca.2014.01.026","article-title":"Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours","volume":"50","author":"Thibault","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdy217_bb1065","unstructured":"European Reference Networks policy 2017; http:\/\/ec.europa.eu\/health\/ern\/policy_en (4 November 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdy217_bb1070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.4521","article-title":"FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: results of an International Global Germ Cell Cancer Group (G3) registry","volume":"35","author":"Cathomas","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb1075","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1097\/01.ju.0000060121.33899.4b","article-title":"Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?","volume":"169","author":"Mosharafa","year":"2003","journal-title":"J Urol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb1080","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-5347(01)65065-1","article-title":"Surgery for a post-chemotherapy residual mass in seminoma","volume":"157","author":"Herr","year":"1997","journal-title":"J Urol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.juro.2016.09.113","article-title":"Clinical outcome of patients with fibrosis\/necrosis at post-chemotherapy retroperitoneal lymph node dissection for advanced germ cell tumors","volume":"197","author":"Mano","year":"2017","journal-title":"J Urol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1756287212443170","article-title":"Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice","volume":"4","author":"Heidenreich","year":"2012","journal-title":"Ther Adv Urol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1095","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2007.10.033","article-title":"Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis","volume":"53","author":"Heidenreich","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb1100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00345-006-0060-8","article-title":"Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer","volume":"24","author":"Beck","year":"2006","journal-title":"World J Urol"},{"issue":"17","key":"10.1093\/annonc\/mdy217_bb1105","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.2003.03.184","article-title":"Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses","volume":"21","author":"Oldenburg","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb1110","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/cncr.10440","article-title":"Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses","volume":"94","author":"Hendry","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb1115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bju.13569","article-title":"Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK\u2014a national study","volume":"119","author":"Wells","year":"2017","journal-title":"BJU Int"},{"issue":"9","key":"10.1093\/annonc\/mdy217_bb1120","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1200\/JCO.2005.05.4791","article-title":"Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma","volume":"25","author":"Carver","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1125","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/JCO.2009.23.0714","article-title":"Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?","volume":"28","author":"Ehrlich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb1130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0022-5347(17)40892-5","article-title":"Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer","volume":"141","author":"Foss\u00e5","year":"1989","journal-title":"J Urol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1135","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdt425","article-title":"A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor","volume":"25","author":"Ravi","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2009.23.0755","article-title":"Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery","volume":"28","author":"Kollmannsberger","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1145","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.1993.11.2.324","article-title":"Surgical salvage of chemorefractory germ cell tumors","volume":"11","author":"Murphy","year":"1993","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0022-5347(05)67365-X","article-title":"Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers","volume":"164","author":"Albers","year":"2000","journal-title":"J Urol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1155","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdt493","article-title":"What are the indications for postchemotherapy retroperitoneal lymph node dissection?","volume":"25","author":"Einhorn","year":"2014","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1093\/annonc\/mdy217_bb1160","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2010.32.6678","article-title":"Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database","volume":"29","author":"Lorch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdy217_bb1165","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2000.18.12.2413","article-title":"Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1170","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjc.6602682","article-title":"A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial","volume":"93","author":"Mead","year":"2005","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb1175","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/0003-4819-109-7-540","article-title":"Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide","volume":"109","author":"Loehrer","year":"1988","journal-title":"Ann Intern Med"},{"issue":"27","key":"10.1093\/annonc\/mdy217_bb1180","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb1185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2006.06.9401","article-title":"Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors","volume":"25","author":"Kondagunta","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb1190","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2011.38.6391","article-title":"Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial","volume":"30","author":"Lorch","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1195","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy217_bb1200","unstructured":"NCT02375204. Standard-dose combination chemotherapy or high-dose combination chemotherapy and stem cell transplant in treating patients with relapsed or refractory germ cell tumors. 2015; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02375204 (12 December 2017, date last accessed)."},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1205","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/annonc\/mdp366","article-title":"High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors","volume":"21","author":"Lorch","year":"2010","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1210","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.1999.17.2.512","article-title":"Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer","volume":"17","author":"Bokemeyer","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1215","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1999.17.2.509","article-title":"Phase II trial of gemcitabine in refractory germ cell tumors","volume":"17","author":"Einhorn","year":"1999","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy217_bb1220","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1200\/JCO.2002.08.050","article-title":"Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group","volume":"20","author":"Kollmannsberger","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb1225","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/(SICI)1097-0142(19980401)82:7<1381::AID-CNCR23>3.0.CO;2-1","article-title":"A phase II trial of paclitaxel in refractory germ cell tumors","volume":"82","author":"Sandler","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb1230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/oxfordjournals.annonc.a010473","article-title":"Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer","volume":"7","author":"Bokemeyer","year":"1996","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb1235","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/1078-1439(95)00064-X","article-title":"Paclitaxel in extensively pretreated nonseminomatous germ cell tumors","volume":"1","author":"Nazario","year":"1995","journal-title":"Urol Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy217_bb1240","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1200\/JCO.1994.12.11.2277","article-title":"Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors","volume":"12","author":"Motzer","year":"1994","journal-title":"J Clin Oncol"},{"issue":"1 Suppl 2","key":"10.1093\/annonc\/mdy217_bb1245","first-page":"36","article-title":"Phase II study of daily oral etoposide in refractory germ cell tumors","volume":"17","author":"Miller","year":"1990","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1250","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2011.06.019","article-title":"Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and\/or multiply relapsed germ cell tumors","volume":"60","author":"Oechsle","year":"2011","journal-title":"Eur Urol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb1255","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/annonc\/mdh103","article-title":"Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study","volume":"15","author":"Pectasides","year":"2004","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy217_bb1260","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.eururo.2006.05.011","article-title":"Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor","volume":"50","author":"De Giorgi","year":"2006","journal-title":"Eur Urol"},{"issue":"7","key":"10.1093\/annonc\/mdy217_bb1265","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1200\/JCO.2002.07.158","article-title":"Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group","volume":"20","author":"Hinton","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1270","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/COC.0b013e31829e19e0","article-title":"Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant","volume":"38","author":"Mulherin","year":"2015","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1275","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.urolonc.2015.11.007","article-title":"Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care\u2013registry data from an outcomes research project of the German Testicular Cancer Study Group","volume":"34","author":"Seidel","year":"2016","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb1280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clgc.2013.07.005","article-title":"Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes","volume":"12","author":"Necchi","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1093\/annonc\/mdy217_bb1285","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2017.09.029","article-title":"Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: implications for assessment of brain metastases","volume":"87","author":"Loriot","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb1290","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0022-5347(01)61781-6","article-title":"Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer","volume":"161","author":"Petersen","year":"1999","journal-title":"J Urol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb1295","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2164\/jandrol.112.016592","article-title":"The semen quality of 1158 men with testicular cancer at the time of cryopreservation: results of the French National CECOS Network","volume":"33","author":"Rives","year":"2012","journal-title":"J Androl"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1300","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6602677","article-title":"Fertility, gonadal and sexual function in survivors of testicular cancer","volume":"93","author":"Huddart","year":"2005","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdy217_bb1305","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/cncr.11950","article-title":"Fertility after testicular cancer treatments: results of a large multicenter study","volume":"100","author":"Huyghe","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb1310","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.1997.15.1.239","article-title":"Fertility after chemotherapy for testicular germ cell cancers","volume":"15","author":"Lampe","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb1315","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2010.03.041","article-title":"Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy","volume":"58","author":"Bryd\u00f8y","year":"2010","journal-title":"Eur Urol"},{"issue":"21","key":"10.1093\/annonc\/mdy217_bb1320","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/jnci\/dji339","article-title":"Paternity following treatment for testicular cancer","volume":"97","author":"Bryd\u00f8y","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb1325","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11764-010-0134-x","article-title":"Fertility among testicular cancer survivors: a case-control study in the U.S","volume":"4","author":"Kim","year":"2010","journal-title":"J Cancer Surviv"},{"issue":"1","key":"10.1093\/annonc\/mdy217_bb1330","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000323346","article-title":"Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients","volume":"34","author":"Cathomas","year":"2011","journal-title":"Oncol Res Treat"},{"issue":"11","key":"10.1093\/annonc\/mdy217_bb1335","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2006.08.4889","volume":"25","author":"Rustin","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy217_bb1340","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/annonc\/mdv254","article-title":"Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience","volume":"26","author":"Chau","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy217_bb1345","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jnci\/djq525","article-title":"Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up","volume":"103","author":"Mead","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1093\/annonc\/mdy217_bb1350","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMra072149","article-title":"Computed tomography\u2014an increasing source of radiation exposure","volume":"357","author":"Brenner","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy217_bb1355","unstructured":"NCCN. Testicular Cancer Version 2.2016, 2016; https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/testicular.pdf (19 December 2016, date last accessed)."},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1360","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0009-9260(97)80105-5","article-title":"The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours","volume":"52","author":"White","year":"1997","journal-title":"Clin Radiol"},{"issue":"6","key":"10.1093\/annonc\/mdy217_bb1365","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/sj.bjc.6603014","article-title":"Late recurrences of germ cell malignancies: a population-based experience over three decades","volume":"94","author":"Oldenburg","year":"2006","journal-title":"Br J Cancer"},{"issue":"28","key":"10.1093\/annonc\/mdy217_bb1370","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1200\/JCO.2014.60.1310","article-title":"Germ cell cancer and multiple relapses: toxicity and survival","volume":"33","author":"Lauritsen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy217_bb1375","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.eururo.2016.03.016","article-title":"Late relapses in stage I testicular cancer patients on surveillance","volume":"70","author":"Mortensen","year":"2016","journal-title":"Eur Urol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341934133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341934133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/8\/1658\/25505131\/mdy217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T22:03:29Z","timestamp":1631829809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341934133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":274,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S092375341934133X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy217","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}